Introduction
We investigated the in vivo effects of a glucocorticoid on fJagonist-induced downregulation of j31-and .82-adrenergic receptors (determined by ["lI] iodocyanopindolol binding), mRNA expression (assessed by Northern blotting), and gene transcription (using nuclear run-on assays) in rat lung. Dexamethasone (Dex) (0.2 mg/kg/d, days 1-8) increased 181-and ,82-receptor numbers by 70 and 69% above control, respectively, but did not change their mRNA expression.
Isoproterenol (Iso) (0.96 mg/kg/d, days 2-8) decreased 813-and .2-receptor numbers by 48 and 51%, respectively, and also reduced mRNA expression by 69 and 57%, respectively. The combination of Dex and Iso resulted in no net change in 182-receptor number and its mRNA expression, although there was a significant reduction in p1-receptor number and mRNA expression. The mapping of (13-and .82-receptors by receptor autoradiography confirmed these findings over alveoli, epithelium, endothelium, and airway and vascular smooth muscle. We also measured the activation of the transcription factor, cyclic AMP response element binding protein (CREB) using an electrophoretic mobility shift assay.
CREB-like DNA-binding activity was decreased after Iso treatment but this decrease was prevented after treatment with Dex. Nuclear run-on assays revealed that the transcrip- (2) . There has been concern that regular use of inhaled /32-agonists may result in tolerance to their beneficial effects in asthma. Although there is no loss of bronchodilator response to /52-agonists, several studies have demonstrated loss of protection against various bronchoconstrictor challenges (3, 4) and this may be relevant to the reduced asthma control seen with the regular use of inhaled 632-agonists (5, 6) . There is a downregulation of P-adrenergic receptors (,/-receptors) in lung after chronic administration of /3-agonists in animals in vivo, although this is less marked in airway smooth muscle than in lung parenchyma (7, 8) . Agonist-promoted downregulation of /2-receptors may be reversed by treatment with glucocorticoids in vitro (9) . Glucocorticoids induce an increase in the synthesis of /-receptors in human and rat lung (10) and restoration of desensitization of /-receptors in human neutrophils and lymphocytes (11, 12) . The reversal of agonist-induced downregulation of the /32-receptor by glucocorticoids has been reported in cultured vas deferens smooth muscle cells (DDT -MF2) at the levels of radioligand binding and of mRNA (13 (15, 17, 18) . Chronic /8-agonist therapy in asthmatic subjects results in reduction in /3-receptor density in circulating polymorphonuclear leukocytes and lymphocytes (19) and the downregulated receptor number is restored with oral prednisone. However, a difference in susceptibility to downregulation between lung and lymphoid tissue has been reported (20) . To investigate whether the in vivo treatment of glucocorticoids prevent the /3-agonistpromoted downregulation of pulmonary /2-receptors, we studied the effects of dexamethasone (Dex) and isoproterenol (Iso) on /2-receptor number, and mRNA expression in rat lung in vivo. In addition, we examined effects on the transcription factor CREB. We also used autoradiographic mapping of /32-receptors to study the effects of Iso and Dex on different cell types in lung. Direct receptor binding techniques using selective /3- antagonists have shown the coexistence of /31-and /2-receptor subtypes in rat and human lung (7, 21 Receptor mapping was performed using the method as described previously (8) . The slides were warmed to room temperature, washed in incubation buffer (25 mM [y32P]ATP (> 5,000 Ci/mmol). Nuclear protein from rat lung was isolated according to a method described previously (7) . Binding reactions between 32P-labeled CREB consensus oligonucleotide and nuclear protein were performed in a final volume of 10 ul in 4% glycerol, 1 mM EDTA, 1 mM DTT, 100 mM NaCl, 10 mM Tris (pH 7.5), and 0.08 mg/ml sonicated salmon sperm DNA. Binding was allowed to proceed for 20 min at room temperature. To resolve the complexes, the reactions were applied to 6% nondenaturing polyacrylamide gels in 0.25 x TBE buffer (10 x TBE is 0.89 M Tris base [pH 8.0], 0.89 M boric acid, and 20 mM EDTA) containing 0.1% ammonium persulfate. The gels were run in 0.25 x TBE buffer at 100 V/cm for 1 h at room temperature with buffer recirculation, then dried and autoradiographed.
The specificity of binding was studied by incubation of 32P-labeled CREB consensus oligonucleotide with nuclear protein in the presence of excess amount of unlabeled oligonucleotide. We have demonstrated previously that CREB-like DNA-binding activity is increased in a concentration-related manner by ,B-agonists in rat lung (26) .
Nuclear run-on transcription assay. To determine whether Dex or Iso changed the transcription rate of 61-and /62-receptor gene, nuclear run-on transcription assays were performed as described previously (27) . Nuclei 
Results
Radioligand receptor binding assay. Chronic injection of Dex Receptor autoradiography. The distribution of #,-and 162-receptors in rat lung (Fig. 2) is in good agreement with previous findings in human and guinea pig lung (8, 28) and confirms and extends the results of the receptor binding study. The increase in /3k-and 02-receptors after Dex, the decrease in both receptor subtypes after Iso, the decrease in ,BI-but no change in /32-receptor after combined treatment of Dex and Iso were found over alveoli, airway epithelium, vascular endothelium, and airway and vascular smooth muscle (Table I) pression by 66±8% (P < 0.01). Electrophoretic mobility shift assay. The specificity of CREB-like DNA-binding activity was demonstrated by the abolition of the single complex formed by excess amount of unlabeled CREB consensus oligonucleotide and the absence of the complex in the control incubation lacking nuclear protein (Fig.  5 A) . Chronic injection of Dex did not significantly affect the CREB-like DNA-binding activity, whereas continuous infusion of Iso significantly reduced the CREB-like DNA-binding activity (P < 0.05). Combined Dex and Iso treatment showed no change in CREB-like DNA-binding activity (Fig. 5, B and C) .
Nuclear run-on transcription assay. The Dex.
Iso.
Dex.+iso.. 3- agonist is also in good agreement with previous in vivo and in vitro studies (7, 8, 19, 31) . When rats were exposed to both Dex and Iso simultaneously, /,1-receptors were reduced, but /2-receptors were unchanged. This protection of dexamethasone on /3-agonist-promoted downregulation of /2-receptors is consistent with the in vitro study using DDT,-MF2 cells (13) .
However, Dex had no protective effect on ,3-agonist-promoted downregulation of /,-receptors.
In agreement with previous reports (7, 8, 31) (7) . Furthermore, our data showed an apparent association between these reductions in mRNA and the reduction in CREB-like DNA-binding activity, suggesting the possible involvement of this transcription factor(s). CREB, a transcription factor, recognizes CRE and stimulates target gene tran- scription (14) . The presence of CRE in the ,82-receptor gene and the ability of /6-agonists to increase intracellular cAMP prompted the suggestion that these elements may be involved in the negative control of transcription (30) . However, this is unlikely since activation of CRE enhances rather than suppresses transcription rates of target genes ( 16) . Thus, it is possible that the reduced CREB-like DNA-binding activity contributes, in part, to the downregulation of /2-receptor mRNA after prolonged exposure to a /-agonist, in good agreement with our previous findings in rat and guinea pig lung (7, 8) . Recently, the presence of a CRE has also been identified in the 5 '-flanking promoter region of the /,-receptor gene (32) and may be involved in the negative control of transcription of this gene.
Although both /,-and /2-receptor densities were increased, neither /,-nor /32-receptor mRNA was increased after chronic in vivo glucocorticoid treatment, in agreement with an in vivo study using Sprague-Dawley rats (33) . In contrast, induction of /2-receptor mRNA by glucocorticoids has been demonstrated in human lung and several cell lines in vitro (17, 18, 34) . The lack of change in the levels of /,1-and /2-receptor mRNAs after dexamethasone in this study may be due to the fact that the accumulation of mRNA is transient. Indeed in our previous study in human lung in vitro (34), we observed that the increase in /32-receptor mRNA was maximal 2 h after exposure to glucocorticoid and returned to baseline by 24 h. Glucocorticoids have the ability to downregulate their own receptors, which act as transcription factors (35) . Several putative GREs are identified in the promoter region of the /32-receptor gene and are obligatory for glucocorticoid regulation of receptor mRNA levels (15 adipocytes, with no effect or an actual decrease in the expression of PI-receptors (29, 36, 37) . 
